ChiCTR-OIC-17010625
结束
/
/
/
2017-02-02
/
/
退化性膝關節炎
先導計劃 - 研究富血小板血漿注射治療退化性膝關節炎
先導計劃 - 研究富血小板血漿注射治療退化性膝關節炎
研究富血小板血漿注射治療退化性膝關節炎
单臂
Ⅱ期
NA
/
NA
/
12
/
1990-01-01
1990-01-01
/
1) Aged 45 to 75 years old; 2) Self-reported symptoms consistent with KOA per American College of Rheumatology guidelines; 3) Have experienced moderate to severe knee pain for at least 3 months, defined as a score of 3 or more (0-6 ordinal response scale) on the question "What is the average level of your left/right knee pain?" 4) Failed 6 months of usual care; 5) Clinical evidence of KOA according to the American College of Rheumatology guidelines; 6) Radiographic evidence of KOA with Kellgren Lawerance (KL).；
请登录查看1) Pregnancy; 2) On anticoagulation, immunosuppressive or daily opioid therapy; 3) History of collagen tissue or other autoimmune disorders; 4) Hematological diseases; 5) Severe cardiovascular diseases; 6) Prior or planned total knee replacement of the affected knee; 7) Allergy or intolerance to acetaminophen or xylocaine; 8) Body mass index (BMI) ≥ 35 kg/m2; 9) Co-morbidity severe enough to prevent reliable or safe study participation; 10) Subjects who cannot read or write in the Chinese Consent form; 11) Interim knee joint infectious arthritis or trauma; 12) Hemoglobin level < 11g/dL; 13) Platelet concentration < 150,000/mm3; 14) Clinical examination suggesting that the patient is not appropriate due to comorbid knee or other conditions.；
请登录查看The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong
/
The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong的其他临床试验
Division of Family Medicine and Primary Health Care, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04